Highly active antiretroviral therapies among HIV-1-infected children in Abidjan, Côte d'Ivoire

AIDS

Volumn 18, Issue 14, 2004, Pages 1905-1913

  Fassinou, Patricia ^a   Elenga, Narcisse ^b   Rouet, François ^c   Laguide, Rockiath ^b   Kouakoussui, Kouakou A ^b   Timite, Marguerite ^a   Blanche, Stephane ^d   Msellati, Philippe ^e,f  

^a Centre Hospitalier of Yopougon   (France)

^b Children's Programme Yopougon/PACCI   (France)

^c Ctr Rech de Diagn du SIDA/PACCI   (France)

^d HÔPITAL NECKER ENFANTS MALADES   (France)

^e INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (France)

^f INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLASE; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; COTRIMOXAZOLE; DIDANOSINE; EFAVIRENZ; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LIVER ENZYME; NELFINAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; VIRUS RNA; ZIDOVUDINE;

ACUTE DIARRHEA; ADOLESCENT; ANEMIA; ARTICLE; CHILD; COHORT ANALYSIS; CONJUNCTIVITIS; CONTROLLED STUDY; DERMATITIS; DRUG TOLERANCE; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INFANT; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NEWBORN; PANCREATITIS; PERIPHERAL NEUROPATHY; PNEUMONIA; PRIORITY JOURNAL; PROBABILITY; SCORING SYSTEM; SIDE EFFECT; SKIN ALLERGY; STOMACH PAIN; SURVIVAL; VIRUS LOAD; VOMITING;

ADOLESCENT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHILD; CHILD, PRESCHOOL; COTE D'IVOIRE; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INFANT; INFANT, NEWBORN; MALE; PATIENT COMPLIANCE; RNA, VIRAL; SURVIVAL ANALYSIS; VIRAL LOAD;

EID: 4744351547     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200409240-00006     Document Type: Article

References (27)

1. UNAIDS, WHO. Report on the Global HIV/AIDS Epidemic. Geneva: UNAIDS and World Health Organization; December 2002: http://www.unaids.org.
2. Spira R, Lepage P, Msellati P, van de Perre P, Leroy V, Simonon A, et al. Natural history of human immunodeficiency virus type 1 infection in children: a five-year prospective study in Rwanda. Pediatrics 1999, 104:p.e56.
3. Taha T, Graham S, Kumwenda N, Broadhead RL, Hoover DR, Markatis D, et al. Morbidity among human immunodeficiency virus-infected and uninfected African children. Pediatrics 2000, 106:p.e 77.
4. Dabis F, Elenga N, Meda N, Leroy V, Viho I, Manigart O, et al. 18-Month mortality and perinatal exposure to zidovudine in West Africa. AIDS 2001, 15:771-779.
5. Lepage P, van de Perre P, van Vliet G, Nsengumuremyi F, Van Goethem C, Kestelyn P, et al. Clinical and endocrinological manifestations in perinatally HIV-1 infected children aged five years or more. Am J Dis Child 1991, 145:1248-1251.
6. Kabore A, Diagbouga S, Manigart O, Hien H, de Oliveira MA, Cassel-Bereau AM, et al. Absence da progression clinique de l'infection par le VIH chez des enfants au Burkina Faso. XII International Congress on AIDS and Sexually Transmitted Diseases in Africa. Ouagadougou, Burkina Faso, December 2001 [abstract PT3-250].
7. Vetter K, Djomand G, Zadi F, Diaby L, Brattegaard K, Timité M, et al. Clinical spectrum of human immunodeficiency virus disease in children in a West African city. Pediatr Infect Dis J 1998,15:438-442.
8. Gortmaker S, Hughes M, Cervia J, M Brady M, Johnson GM, Seage GR, et al. Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1. N Eng J Med 2001, 345:1522-1528.
9. van Rossum A, Scherpbier H, van Lochem EG, Pakker NG, Slieker WAT, Wolthers KC, et al. Therapeutic immune reconstitution in HIV-1-infected children is independent of their age and pretreatment immune status. AIDS 2001, 15:2267-2275.
10. van Rossum A, Geelen S, Hartwig N, Wolfs TFW, Weemaes CMR, Scherpbier HJ, et al. Results of 2 years of treatment with protease-inhibitor-containing antiretroviral therapy in Dutch children infected with human immunodeficiency virus type 1. Clin Infect Dis 2002, 34:1008-1016.
11. Essajee S, Kim M, Gonzalez C, Rigaud M, Kaul A, Chandwani S, et al. Immunologic and virologic responses to HAART in severely immunocompromised HIV-1 infected children. AIDS 1999, 13:2523-2532.
12. Teglas J, Mayaux M, Blanche S. Antiretroviral therapy and mortality among children with perinatal HIV infection. JAMA 2000, 284:2871-2872.
13. van Rossum AM, Fraaij PL, de Groot R. Efficacy of highly active antiretroviral therapy in HIV-1 infected children. Lancet Infect Dis 2002, 2:93-102.
14. Chêne C, Binquet C, Moreau JF, Neau D, Pellegrin I, Malvy D, et al. Changes in CD4 cell count and the risk of opportunistic infection or death after highly active antiretroviral treatment. AIDS 1998, 12:2313-2320.
15. Badri M, Wilson D, Wood R. Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet 2002, 359:2059-2064.
16. Weidle PJ, Malamba S, Mwebaze R, Sozi C, Rukundo C, Downing R, et al. Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients' response, survival and drug resistance. Lancet 2002, 360:34-40.
17. Laurent C, Diakhaté N, Gueye NN, Touré MA, Sow PS, Faye MA, et al. The Senegalese government's highly active antiretroviral therapy initiative: an 18-month follow-up study. AIDS 2002, 16:1363-1370.
18. Djomand C, Roels T, Ellerbrock T, Hanson D, Diomande F, Monga B, et al. Virologic and immunologic outcomes and programmatic challenges of an antiretroviral treatment pilot project in Abidjan, Côte d'Ivoire. AIDS 2003, 17(suppl 3): S5-S16.
19. Anon. Use of Antiretroviral Drugs in the Management of HIV-infected Persons. Dakar: ANRS/IMEA/IRD/SAA/UNAIDS/PNLS Sénégal/PNLS CI, IAS; 2000.
20. UNAIDS/WHO. Provisional WHO/UNAIDS secretariat recommendations on the use of cotrimoxazole prophylaxis in adults and children living with HIV/AIDS in Africa. Geneva: UNAIDS and World Health Organization; 2000 http://www.unaids. org/ publications/documents/care/general/recommendation-eng.pdf.
21. Rouet F, Montcho C, Rouzioux C, Leroy V, Msellati P, Kottan JB, et al. Early diagnosis of paediatric HIV-1 infection among African breast-fed children using a quantitative plasma HIV RNA assay. AIDS 2001, 15:1849-1856.
22. Centers for Disease Control and Prevention. 1994 revised classification systems for human immunodeficiency virus infection in children less than 13 years of age. MMWR 1994, 43:1-19.
23. Juillet A, Malaval C, Msellati P, Moatti J. The impact of the UNAIDS Initiative on HIV/AIDS treatments in Côte d'Ivoire. XIII International AIDS Conference. Durban, July 2000 [late breakers].
24. Aka Dago-Akribi LH, Dossou R. Psychological support to HIV-infected pre-teens and teenagers. XIV International Conference on AIDS. Barcelona, July 2002 [abstract F12392].
25. Nachman SA, Lindsey JC, Pelton S, Mofenson L, McIntosh K, Wiznia A, et al. Growth in human immunodeficiency virus-infected children receiving ritonavir-containing antiretroviral therapy. Arch Pediatr Adolesc Med 2002, 156:497-503.
26. Verweel G, van Rossum AM, Hartwig NG, Wolfs TF, Scherpbier HJ, de Groot R. Treatment with highly active antiretroviral treatment in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth. Pediatrics 2002, 109:E25.
27. Rabkin M, El-Sadr W, Katzenstein DA, Mukherjee J, Masur H, Mugyenyi P, et al. Antiretroviral treatment in resource-poor settings: clinical research priorities. Lancet 2002, 360: 1503-1505.